Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

BK Polyomavirus Clinical Trial

— BK-CTLs  

Official title:

A Pilot Study in the Treatment of BK Virus Infection With Cytotoxic T Cells in Immunocompromised Transplant Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04293042
• Other study ID #: 19-016545
• Status: Recruiting
• Phase: Early Phase 1
• Start date: October 7, 2019
• Est. completion date: December 30, 2025

Study information

• Verified date: January 2024
• Source: Children's Hospital of Philadelphia
• Contact: Patricia Hankins, BSN, RN, CCRC
• Phone: 215-590-5168
• Email: hankinsp[@]chop.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

Description:

This open-label, single-arm clinical trial will assess the safety and efficacy of BK virus-specific CTLs isolated from whole blood or leukapheresis products. The BK virus -specific CTLs will be generated automatically by the CliniMACS® Prodigy using the CliniMACS Cytokine Capture System (IFNgamma) after incubation with MACS GMP PepTivator® Peptide Pools of BKV VP1 and BKV LT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Weeks to 25 Years

Eligibility

Inclusion Criteria:

Patient Eligibility

• Patients with symptoms of cystitis and elevated BK virus DNA by screening PCR as above (section 4) post allogeneic HSCT, post chemotherapy

1. Symptoms of cystitis may include: hematuria (microscopic or gross), pain with urination, frequency, bladder spasms.

2. Patient may be otherwise treated for cystitis as per local institutional standards. Such treatments may include hydration, antiviral medications, or surgical intervention as deemed appropriate by treating physician.

• Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.

• Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs)

• Age: 0.1 to 25 years

• Females of childbearing potential with a negative urine pregnancy test.

Donor Eligibility

• Related donor available with a T-cell response to the BK-virus MACS® PepTivator® antigen(s).

1. Original allogeneic donor if available, IgG positive for BKV or confirmatory testing to respond to BKV MACS Peptivator®.

2. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor > 1 HLA A, B, DR match to recipient) with a T-cell response to the BK MACS® PepTivator.

AND

• Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).

AND

• Obtained informed consents by donor or donor legally authorized representative prior to donor collection.

Exclusion Criteria:

Patient exclusion criteria:

A patient meeting any of the following criteria is not eligible for the present study:

• Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of BK Virus CTL infusion

• Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of BK Virus CTL infusion or within 3 days of planned infusion.

• Thymoglobulin (ATG), campath or T cell immunosuppressive monoclonal antibodies within 30 days

• Patient with poor performance status determined by Karnofsky (patients >16 years) or Lansky (patients =16 years) score =30%

• Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK virus infection.

• Any medical condition which could compromise participation in the study according to the investigator's assessment

• Known HIV infection

• Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.

• Known hypersensitivity to iron dextran

• Patients unwilling or unable to comply with the protocol or unable to give informed consent.

• Known human anti-mouse antibodies

Related Conditions & MeSH terms

• BK Polyomavirus
• Virus Diseases

Intervention

Biological:
• BK-virus specific CTLs
HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg). HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg).

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Grade III-IV acute GVHD	Number of participants with Grade III-IV acute GVHD as assessed by CTCAE v4.0	Up to 8 weeks after last BK-CTL infusion
Primary	Number of patients with undetectable BK viral load	Number of patients with undetectable BK viral load as measured by qPCR	12 weeks after first BK-CTL infusion